Managing chronic pelvic pain following reconstructive pelvic surgery with transvaginal mesh.
In 2001, the US Food and Drug Administration (FDA) approved the first transvaginal mesh kit to treat pelvic organ prolapse (POP). Since the introduction of vaginal mesh kits, some vaginal meshes have been associated with chronic pelvic pain after reconstructive pelvic floor surgery. Pelvic pain results in between 0 % and 30 % of patients following transvaginal mesh placement. Common causes of chronic pelvic pain include pelvic floor muscle spasm, pudendal neuralgia, and infection. Paucity of data exists on the effective management of chronic pelvic pain after pelvic reconstructive surgery with mesh. We outline the management of chronic pelvic pain after transvaginal mesh placement for reconstructive pelvic floor repair based on our clinical experience and adaptation of data used in other aspects of managing chronic pelvic pain conditions.
Minimally Invasive Gynecology, 3004 17th Street, St Cloud, FL, 34769, USA, tonygyang@hotmail.com.
Anthony N
AN
Gyang
Jessica B
JB
Feranec
Rakesh C
RC
Patel
Georgine M
GM
Lamvu
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D059350:Chronic Pain / Q000209:etiology / Q000628:therapy*; D020878:Device Removal; D005260:Female; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use; D059408:Pain Management; D010149:Postoperative Pain / Q000209:etiology / Q000628:therapy*; D017773:Pelvic Floor / Q000503:physiopathology; D056887:Pelvic Organ Prolapse / Q000601:surgery; D017699:Pelvic Pain / Q000209:etiology / Q000628:therapy*; D026741:Physical Therapy Modalities; D019919:Prosthesis Implantation / Q000009:adverse effects; D016459:Prosthesis-Related Infections / Q000150:complications / Q000628:therapy; D060545:Pudendal Neuralgia / Q000150:complications / Q000628:therapy; D013035:Spasm / Q000150:complications / Q000188:drug therapy; D013526:Surgical Mesh / Q000009:adverse effects* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D014150:Antipsychotic Agents; D009465:Neuromuscular Agents